In the news release, Ampa Launches Nationwide Rollout of Portable FDA-Cleared Brain Stimulation System Following $8.5M Oversubscribed Funding Round, issued Oct. 22, 2025 by Ampa over PR Newswire, we are advised by a representative of the company that the first paragraph, last sentence, should read “This milestone marks a major step in bringing advanced, non-invasive brain stimulation to patients across the country and brings Ampa's total funding to $18 million” rather than “This milestone marks a major step in bringing advanced, non-invasive brain stimulation to patients across the country” as originally issued inadvertently. The complete, corrected release follows:
Ampa Launches Nationwide Rollout of Portable FDA-Cleared Brain Stimulation System Following $8.5M Oversubscribed Funding Round
Four months after emerging from stealth with FDA clearance of theAmpa One system and an oversubscribed $8.5 million round led by Nexus NeuroTech Ventures, Ampa today announced its nationwide rollout. This milestone marks a major step in bringing advanced, non-invasive brain stimulation to patients across the country and brings Ampa's total funding to $18 million.
https://mma.prnewswire.com/media/2801767/1.jpg
“We've never been more depressed yet more medicated. People deserve new options,” said Don Vaughn, Ph.D., neuroscientist and CEO of Ampa. “Ampa One was built to give clinicians a practical, portable, affordable tool that expands patient access to this lifesaving technology.”
In addition to its FDA-cleared device, the company is developing the Ampa One Day protocol, a groundbreaking approach that condenses a traditional multi-week TMS treatment into a single day. This innovation could define a new category of rapid-acting treatments for mental health.
“Ampa represents a revolution in TMS therapy,” says Tobias Marton, M.D., Ph.D., and CMO of Mindful Health Solutions. “Our clinical team has been impressed by its portability, intuitive design, and confirmed target engagement-features that redefine how and where TMS can be delivered. By enabling scalable next-generation protocols, Ampa is opening the door to broader access and better outcomes. Kudos to the Ampa team for bringing this transformative system to market.”
Investors see Ampa as a company poised to reshape the mental health landscape. The company recently closed an oversubscribed Pre-A round, led by a $2 million investment from Nexus NeuroTech Ventures, a leading venture capital firm advancing treatments for brain disorders. Other institutional investors included Satori Capital, Morningside Ventures, Continuum Health Ventures, and the Zabara Foundation, alongside new and existing individual investors-physicians, TMS insiders, and mission-aligned entrepreneurs.
“Ampa is setting a new standard for what neuromodulation can look like in clinical practice,” said John Propst, Ph.D., MBA, Principal at Nexus NeuroTech Ventures. “We're proud to support a company that is delivering both scientific innovation and operational scalability at the same time.”
Ampa's launch into commercial deployment reflects growing momentum in the field of non-invasive brain stimulation. With hundreds of millions affected by depression, anxiety, and related conditions, the company's vision is to make remission the default, not the exception.
About Ampa
Ampa is a neurotechnology company using breakthroughs in neuroscience to create practical tools that help people recover their mental health. Its FDA-cleared Ampa One system and emerging Ampa One Day protocol advance the mission of one billion remissions from mental and neurological disorders. Learn more atwww.ampahealth.com
Media Contact:
Itamar Kandel(415) 463-3454403271@email4pr.com
https://mma.prnewswire.com/media/2801768/2.jpg
https://edge.prnewswire.com/c/img/favicon.png?sn=PH03399A&sd=2025-10-22
View original content to download multimedia:https://www.prnewswire.com/news-releases/ampa-launches-nationwide-rollout-of-portable-fda-cleared-brain-stimulation-system-following-8-5m-oversubscribed-funding-round-302590882.html
SOURCE Ampa
https://rt.newswire.ca/rt.gif?NewsItemId=PH03399&Transmission_Id=202510221525PR_NEWS_USPR_____PH03399A&DateId=20251022